&nbsp;

Feb 2024

Drug

lenalidomide

Other Name(s): Revlimid®

Quick Link(s):

Mar 2024

Drug

lomustine

Other Name(s): CeeNU®

Quick Link(s):

Aug 2024

Drug

lanreotide

Other Name(s): Somatuline® Autogel®

Quick Link(s):

Jun 2024

Regimen

LOMU

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

Drugs Used:

lomustine

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

LANR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

lanreotide

Drugs Used:

lanreotide

Quick Link(s):

Regimen Monograph

May 2024

Regimen

LOMU+BEVA

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma

Drugs Used:

lomustine,

bevacizumab

Quick Link(s):

Regimen Monograph

May 2024

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Drugs Used:

larotrectinib

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen

ZANU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria

Drugs Used:

zanubrutinib

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

ZANU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.

Drugs Used:

zanubrutinib

Quick Link(s):

Regimen Monograph

Mar 2024

Drug

zanubrutinib

Other Name(s): Brukinsa®

Quick Link(s):